Atossa Genetics to Present at Upcoming Investor Conferences

SEATTLE, WA--(Marketwired - Oct 9, 2015) - Atossa Genetics Inc. (NASDAQ: ATOS) a healthcare company focused on improving breast health through the development of pharmaceuticals to treat breast health conditions and through commercialization of medical devices and laboratory tests, today announced that it will be a featured presenter at the Dawson James Securities conference being held on Thursday, October 15, 2015 at the Wyndham Grand Hotel, Jupiter, FL. Kyle Guse, CFO and General Counsel, will present the Company's business model and growth strategy at 1:15 pm EDT in Track One. Atossa Genetics is also a featured presenter at the 14th Annual BIO Investor Forum at the Parc 55 Hotel, San Francisco, CA, where Mr. Guse will present on Tuesday, October 20, 2015 at 3:00 pm PDT, in the Fillmore room.

About Atossa Genetics

Atossa Genetics Inc. is focused on improving breast health through the development of therapeutics, medical devices and laboratory services. The laboratory services are being developed by its subsidiary, The National Reference Laboratory for Breast Health, Inc. The laboratory's services and the Company's medical devices are being developed so they can be used as companions to therapeutics to treat various breast health conditions. For more information, please visit www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa to sell its products, responses to regulatory matters, Atossa's ability to achieve its objectives and continue to manufacture and sell its products, recalls of products, the safety and efficacy of Atossa's products and services, performance of distributors and investigators, whether Atossa can launch in the United States and foreign markets the additional tests, devices and therapeutics in its pipeline in a timely and cost effective manner, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.